Avantor, Inc. (NYSE:AVTR – Get Free Report) EVP James Bramwell sold 3,758 shares of Avantor stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total transaction of $65,877.74. Following the sale, the executive vice president now directly owns 87,379 shares of the company’s stock, valued at $1,531,753.87. This trade represents a 4.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Avantor Stock Up 1.3 %
Avantor stock opened at $16.71 on Friday. The firm has a market cap of $11.37 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 1.55 and a beta of 1.28. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.07 and a quick ratio of 0.70. Avantor, Inc. has a fifty-two week low of $16.41 and a fifty-two week high of $28.00. The firm has a fifty day moving average price of $20.51 and a two-hundred day moving average price of $22.67.
Avantor (NYSE:AVTR – Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same quarter last year, the business posted $0.22 earnings per share. As a group, analysts forecast that Avantor, Inc. will post 1.06 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities research analysts have issued reports on AVTR shares. Barclays decreased their target price on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Stifel Nicolaus decreased their target price on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, February 10th. Raymond James reissued an “outperform” rating and set a $24.00 target price (down previously from $26.00) on shares of Avantor in a research note on Monday, February 10th. Morgan Stanley reduced their price objective on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Finally, Wells Fargo & Company reduced their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.92.
Get Our Latest Report on Avantor
Avantor Company Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Further Reading
- Five stocks we like better than Avantor
- Using the MarketBeat Stock Split Calculator
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Transportation Stocks Investing
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.